OM is one of the cheapest trials we could run. Literally a mouth wash. Swish and spit. Also it's phase 3 which will bring lots of interest.
$350M market cap isn't very high for a phase 3 company. That's 10x from here just for starting the trial on an indication that is almost certain to succeed.